BUSINESS

United States drug ad war pits Novo Nordisk against Lilly

▪

Read, Watch or Listen

Novo Nordisk has filed a federal lawsuit in the U.S. District Court for the District of New Jersey accusing Eli Lilly of running deceptive nationwide advertising campaigns for its obesity and diabetes drugs Zepbound and Mounjaro. The complaint, lodged on Tuesday, alleges violations of federal and state false advertising and unfair competition laws, including the Lanham Act. Novo Nordisk claims Lilly used outdated clinical trial data to suggest Zepbound patients lost an average of 50 pounds versus 33 pounds on Novo’s Wegovy, while allegedly comparing a higher Zepbound dose to an older, lower Wegovy dose and omitting newer Wegovy formulations now available.

Prepared by Christopher Adams and reviewed by editorial team.

Timeline of Events

End of decade Analysts forecast $120 billion market
Earlier trials Generate weight-loss data for comparisons
Recent years Novo and Lilly expand GLP-1 portfolios
Tuesday Novo Nordisk files federal lawsuit
Tuesday Case assigned to New Jersey district court
After filing Lawsuit cites Lanham Act violations
After filing Complaint challenges Lilly’s efficacy claims
Going forward Court to review advertising evidence

Why This Matters to You

This lawsuit could impact the information you see about obesity and diabetes drugs. If Novo Nordisk wins, it may force Lilly to change its advertising. That means more accurate data for you when choosing a medication. Check with your doctor about the latest drug trials and formulations.

The Bottom Line

This is a battle over truth in advertising in a booming $120 billion market. It's a reminder to always question the claims of drug companies. Worth forwarding if you know someone taking Zepbound or Wegovy.